-->

Sunshine Biopharma Stock Price To Earning

SBFM Stock  USD 1.46  0.05  3.55%   
Fundamental analysis of Sunshine Biopharma allows traders to better anticipate movements in Sunshine Biopharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
  
Build AI portfolio with Sunshine Stock
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sunshine Biopharma Company Price To Earning Analysis

Sunshine Biopharma's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current Sunshine Biopharma Price To Earning

    
  1.07 X  
Most of Sunshine Biopharma's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sunshine Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Sunshine Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Sunshine Biopharma is extremely important. It helps to project a fair market value of Sunshine Stock properly, considering its historical fundamentals such as Price To Earning. Since Sunshine Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sunshine Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sunshine Biopharma's interrelated accounts and indicators.
1.0-0.91-0.960.940.981.0-0.330.240.470.880.960.8-0.230.851.01.00.61-0.66-0.59-0.66
1.0-0.91-0.940.950.971.0-0.340.20.50.860.970.8-0.240.831.01.00.59-0.67-0.61-0.67
-0.91-0.910.86-0.74-0.9-0.930.31-0.4-0.49-0.77-0.78-0.50.26-0.75-0.93-0.93-0.580.330.570.33
-0.96-0.940.86-0.9-0.98-0.960.27-0.3-0.4-0.95-0.92-0.780.12-0.94-0.95-0.96-0.760.620.520.62
0.940.95-0.74-0.90.910.93-0.310.050.430.830.990.93-0.20.810.930.920.53-0.85-0.56-0.85
0.980.97-0.9-0.980.910.98-0.30.370.370.920.920.77-0.160.90.980.980.7-0.63-0.5-0.63
1.01.0-0.93-0.960.930.98-0.330.270.480.880.950.77-0.240.851.01.00.62-0.63-0.59-0.63
-0.33-0.340.310.27-0.31-0.3-0.33-0.06-0.42-0.33-0.31-0.340.51-0.39-0.33-0.33-0.320.210.330.21
0.240.2-0.4-0.30.050.370.27-0.06-0.050.390.02-0.160.040.360.280.270.420.19-0.080.19
0.470.5-0.49-0.40.430.370.48-0.42-0.050.380.450.33-0.330.390.480.490.1-0.29-0.59-0.29
0.880.86-0.77-0.950.830.920.88-0.330.390.380.840.75-0.180.960.880.890.75-0.61-0.52-0.61
0.960.97-0.78-0.920.990.920.95-0.310.020.450.840.92-0.210.820.950.950.55-0.81-0.58-0.81
0.80.8-0.5-0.780.930.770.77-0.34-0.160.330.750.92-0.080.740.770.770.48-0.9-0.45-0.9
-0.23-0.240.260.12-0.2-0.16-0.240.510.04-0.33-0.18-0.21-0.08-0.17-0.23-0.24-0.060.140.160.14
0.850.83-0.75-0.940.810.90.85-0.390.360.390.960.820.74-0.170.850.860.87-0.59-0.43-0.59
1.01.0-0.93-0.950.930.981.0-0.330.280.480.880.950.77-0.230.851.00.62-0.64-0.59-0.64
1.01.0-0.93-0.960.920.981.0-0.330.270.490.890.950.77-0.240.861.00.63-0.63-0.59-0.63
0.610.59-0.58-0.760.530.70.62-0.320.420.10.750.550.48-0.060.870.620.63-0.25-0.14-0.25
-0.66-0.670.330.62-0.85-0.63-0.630.210.19-0.29-0.61-0.81-0.90.14-0.59-0.64-0.63-0.250.391.0
-0.59-0.610.570.52-0.56-0.5-0.590.33-0.08-0.59-0.52-0.58-0.450.16-0.43-0.59-0.59-0.140.390.39
-0.66-0.670.330.62-0.85-0.63-0.630.210.19-0.29-0.61-0.81-0.90.14-0.59-0.64-0.63-0.251.00.39
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Sunshine Retained Earnings

Retained Earnings

(65.59 Million)

Sunshine Biopharma reported last year Retained Earnings of (69.04 Million)
Based on the latest financial disclosure, Sunshine Biopharma has a Price To Earning of 1.07 times. This is 95.86% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to earning for all United States stocks is 96.27% higher than that of the company.

Did you try this?

Run Equity Search Now

   

Equity Search

Search for actively traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Sunshine Fundamentals

About Sunshine Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
Check out Sunshine Biopharma Piotroski F Score and Sunshine Biopharma Altman Z Score analysis.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.76)
Revenue Per Share
29.768
Quarterly Revenue Growth
0.18
Return On Assets
(0.12)
Return On Equity
(0.21)
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.